Novel Early Detection Strategy for Liver Cancer using Hepatitis B Splice Variants to Expediate Diagnosis and Improve Treatment Outcome

使用乙型肝炎剪接变体的肝癌早期检测新策略以促进诊断并改善治疗结果

• 批准号: nhmrc : 1145977
• 负责人: A/Pr Peter Revill
• 金额: $ 63.8万
• 依托单位: Melbourne Vic.
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/novel-early-detection-treatment-outcome/1320568
• 关键词: Novel; Early; Detection; Strategy; Liver

Hepatitis B virus (HBV) causes liver cancer, which is one of the only cancers that is increasing in prevalence. We have shown that smaller versions of HBV, termed splice variants, are even more strongly associated with liver cancer- people with higher levels of the splice variants were over 3 times more likely to have liver cancer. We will find out why, by thoroughly studying how the splice variants alter the virus and the host cell to promote liver cancer.

B型肝炎病毒（HBV）导致肝癌，这是患病率增加的仅有的癌症之一。我们已经证明，较小版本的HBV（称为剪接变异体）与肝癌的相关性更强-剪接变异体水平较高的人患肝癌的可能性超过3倍。我们将通过彻底研究剪接变异体如何改变病毒和宿主细胞来促进肝癌来找出原因。